Mersana Therapeutics, Inc.

Second-quarter 2025 collaboration revenue was $3.1 million, up from $2.3 million a year earlier. R&D expense was $16.2 million versus $17.2 million in Q2 2024, and G&A expense was $7.4 million versus $10.5 million. Net loss was $24.3 million, flat versus the prior-year quarter. Cash and cash equivalents were $77 million at quarter-end; net cash used in operating activities was $22.6 million, including $2.4 million of severance-related payments. In July, the company paid about $17.9 million to retire its debt facility. Forward-looking, Mersana expects its capital resources to fund current operating plan commitments into mid-2026, excluding any future milestone receipts. Management also reiterated that initial clinical data from Emi-Le expansion should come in the second half of 2025, and it is hoping to share some pharmacodynamic data for XMT-2056, though it is not committing to dose-escalation data this year.

Marty Huber framed the quarter around Emi-Le’s clinical progress and the opportunity in post-topo TNBC. He pointed to ASCO and ESMO presentations, said enrollment in expansion has been strong, and argued that the market for post-topo TNBC could grow as topo-1 ADCs move earlier in treatment lines. His tone was constructive and data-driven, but he repeatedly emphasized that the next inflection point is the second-half expansion readout and that future development choices will be guided by those data.

Brian DeSchuytner focused on liquidity, spending discipline, and the near-term capital picture. He said the company ended Q2 with $77 million in cash and cash equivalents, used $22.6 million of operating cash in the quarter, and paid roughly $17.9 million to eliminate the debt facility in July. He also noted the revenue and expense trends: collaboration revenue of $3.1 million, R&D of $16.2 million, G&A of $7.4 million, and a quarterly net loss of $24.3 million. He reiterated that the cash runway guidance into mid-2026 does not include future milestone payments.

Analysts focused on what will be in the second-half Emi-Le expansion data, including follow-up duration, the mix between dose A and dose B, and whether the data would be enough to decide between doses. Management said the dataset should be based on the more than 45 enrolled patients, that dose A will have longer follow-up than dose B, and that the company expects enough data to evaluate efficacy, safety, durability, and the effect of proteinuria mitigation. Questions also centered on proteinuria management and pivotal-trial design; Mersana said Amendment 5 added prophylactic ACE inhibitor/ARB use and allowed continued dosing despite isolated albuminuria, and it is considering a randomized post-topo study that could potentially broaden beyond classic TNBC, including HER2-low patients, pending regulatory discussions.